Gilead Sciences to Present at Two Upcoming Investor Conferences on Tuesday, June 10

  Gilead Sciences to Present at Two Upcoming Investor Conferences on Tuesday,   June 10              - William Blair 34^th Annual Growth Stock Conference -           - Goldman Sachs 35^th Annual Global Healthcare Conference -             - Webcasts Available Through Gilead Corporate Website -  William Blair Growth Stock Conference 2014 Goldman Sachs 35th Annual Global Healthcare Conference 2014  Business Wire  FOSTER CITY, Calif. -- June 9, 2014  Gilead Sciences, Inc. (Nasdaq: GILD) today announced that its corporate presentation will be webcast from two upcoming investor conferences: the William Blair 34^th Annual Growth Stock Conference in Chicago and the Goldman Sachs 35^th Annual Global Healthcare Conference in Rancho Palos Verdes.  John F. Milligan, PhD, Gilead’s President and Chief Operating Officer, will provide an overview of the company at the William Blair conference on Tuesday, June 10 at 10:50 a.m. Central Time.  Robin L. Washington, Gilead’s Executive Vice President and Chief Financial Officer, will provide an overview of the company at the Goldman Sachs conference on Tuesday, June 10 at 10:00 a.m. Pacific Time.  To access the live webcast or a replay via the internet log on to www.gilead.com. Please connect to the company’s website at least 15 minutes prior to the start of the presentation to ensure adequate time for any software download that may be necessary to listen to the webcast. The replay will be available for 14 days following the presentation.  About Gilead  Gilead Sciences is a biopharmaceutical company that discovers, develops and commercializes innovative therapeutics in areas of unmet medical need. The company’s mission is to advance the care of patients suffering from life-threatening diseases worldwide. Headquartered in Foster City, California, Gilead has operations in North and South America, Europe and Asia Pacific.   For more information on Gilead Sciences, please visit www.gilead.com or call    the Gilead Public Affairs Department at 1-800-GILEAD-5 (1-800-445-3235).  Contact:  Gilead Sciences Patrick O’Brien, 650-522-1936 Investor Relations  
Press spacebar to pause and continue. Press esc to stop.